Planned in cooperation with the Hematology/Oncology Pharmacy Association and the American College of Clinical Pharmacy
3.0 Contact Hours / Knowledge-based
Educational Content: Level 3
Moderator: Casey B. Williams, PharmD, BCOP, Hematology/Oncology Clinical Coordinator and Residency Director, University of Kansas Hospital, Kansas City; and Chair, HOPA/BCOP Recertification Committee, Hematology/Oncology Pharmacy Association

Please note: If you are attending this program for BCOP recertification, there are different instructions for claiming CE from those attending only for ACPE credit.

ACPE Credit Only: Instructions for claiming CE will be available in the session room. CE will be provided by the Hematology/Oncology Pharmacy Association (HOPA).

BCOP Recertification: These sessions are part of the professional development program for recertification of Board Certified Oncology Pharmacists (BCOPs), approved by the Board of Pharmaceutical Specialities (BPS). Part II will be presented on Tuesday, December 8, 2:00 p.m. to 5:00 p.m. BCOPs must attend all six hours of programming to be eligible to complete the Web-based post-test for oncology recertification credit. Partial credit is not available for recertification, but is available for ACPE credit.

In the session room, you must complete a paper registration form and swipe your Electronic Business Card (received at Registration) in the card reader provided in the session room. You must swipe your card Electronic Business Card in both the morning and afternoon session as you enter and exit the session room.

The post-test fee is $45. After the Midyear Clinical Meeting, porgram participants will receive email instructions to purchase and access the test, as well as claim ACPE credit. The post-test examination must be completed and submitted by December 31, 2009.

8:00 a.m. - 9:00 a.m.
Update in Central Nervous System Malignancies
ACPE Activity #465-000-09-011-L01-P - 1.0 Contact Hour
Presenter: John Valgus, PharmD, BCOP, Hematology/Oncology Clinical Pharmacist Practitioner, University of North Carolina Hospitals and Clinics, Chapel Hill, Clinical Assistant Professor, University of North Carolina Eshelman School of Pharmacy, Chapel Hill

Learning Objectives:

• Identify the role of bevacizumab in the treatment of glioblastoma multiforme.
  
• Describe current treatment recommendations for anaplastic astrocytoma and CNS lymphoma.
  
• Identify chemotherapy options for patients with brain metastases.
  
• Discuss issues surrounding anticoagulation in patients with brain metastases.
  

9:00 a.m. - 10:00 a.m.
To 'Nib' or To Cut? 2009 Hepatocellular Carcinoma Update
ACPE Activity #465-000-09-009-L01-P - 1.0 Contact Hour
Presenter: Jolynn K. Sessions, PharmD, BCOP, Oncology Clinical Pharmacist Specialist, Charles George VA, Asheville, NC

Learning Objectives:

• Evaluate efficacy and toxicity of chemotherapy regimens for hepatocellular toxicity.
  
• Discuss current role of sorafenib in the treatment of hepatocellular carcinoma, based on the SHARP trial and other trial data.
  
• Review pivotal ongoing phase I and II studies in hepatocellular carcinoma.
  
• Summarize current treatment of hepatocellular carcinoma based on stage.
  

10:00 a.m. - 11:00 a.m.
Pharmacogenomics: Application in Cancer Patients
ACPE Activity #465-000-09-008-L01-P - 1.0 Contact Hour
Presenter: John Kuhn, PharmD, FCCP, BCOP, Professor, University of Texas College of Pharmacy, San Antonio

Learning Objectives:

• Describe the difference between pharmacogenetics and pharmacogenomics.
  
• Illustrate the use of genomic terminology in the application of pharmacogenomics.
  
• Provide a list of the validated polymorphic enzymes you would recommend for genotyping prior to chemotherapy.
  
• Discuss the emerging genetic polymorphisms that influence the pharmacokinetics and/or pharmacodynamics of cancer therapeutics.